Free tool
FAERS Monitor: Siklos
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208843 or its brand name (Siklos, Hydroxyurea). Reports on generic versions are filed under their own applications.
Reports
15,166
Serious
10,933
72% of reports
Hospitalization
5,380
Death reported
2,105
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,798
- sickle cell anaemia with crisis1,320
- fatigue1,174
- diarrhoea1,118
- nausea1,014
- headache841
- death786
- product dose omission issue775
- drug ineffective748
- haemoglobin decreased688
- anaemia678
- pain666
- pyrexia602
- dyspnoea594
- asthenia569
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 91 |
| 2005 | 99 |
| 2006 | 141 |
| 2007 | 140 |
| 2008 | 141 |
| 2009 | 151 |
| 2010 | 187 |
| 2011 | 251 |
| 2012 | 340 |
| 2013 | 220 |
| 2014 | 379 |
| 2015 | 466 |
| 2016 | 725 |
| 2017 | 877 |
| 2018 | 1,091 |
| 2019 | 974 |
| 2020 | 1,273 |
| 2021 | 1,484 |
| 2022 | 1,623 |
| 2023 | 1,508 |
| 2024 | 1,194 |
| 2025 | 1,071 |
| 2026 | 740 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,993 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sickle cell anaemia with crisisSignal | 1,320 | 126.7 | 120.0 | 150,814 |
| haemoglobin decreasedSignal | 688 | 9.3 | 8.7 | 5,112 |
| anaemiaSignal | 678 | 4.9 | 4.6 | 2,141 |
| product dose omission issueSignal | 775 | 3.7 | 3.4 | 1,514 |
| off label useSignal | 1,798 | 2.9 | 2.7 | 2,249 |
| pyrexiaSignal | 602 | 2.4 | 2.2 | 505 |
| diarrhoeaSignal | 1,118 | 2.4 | 2.3 | 943 |
| astheniaSignal | 569 | 2.1 | 1.9 | 332 |
| fatigueSignal | 1,174 | 2.1 | 2.0 | 694 |
| headache | 841 | 1.9 | 1.7 | 344 |
| nausea | 1,014 | 1.8 | 1.7 | 357 |
| pain | 666 | 1.5 | 1.4 | 115 |
| dyspnoea | 594 | 1.5 | 1.3 | 87 |
| death | 786 | 1.3 | 1.2 | 45 |
| drug ineffective | 748 | 0.8 | 0.7 | 46 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.